Search clinical trials for: Sublingual immunotherapy

Total 4388 results

Tongji Hospital

Not yet recruiting

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Hepatocellular Carcinoma

China
Tongji Hospital

Not yet recruiting

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...
Peking University Cancer Hospital & Institute

Recruiting

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Esophageal Neoplasm Metastatic | Esophageal Cancer Stage IVb

China
Zhiyong Huang
Wuhan Elongevity Technology Co., Ltd.

Recruiting

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

Liver Cancer

China
Indiana University

Recruiting

Organoid Model Predictive of Response to Immunotherapies

Breast Cancer

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
The First Affiliated Hospital with Nanjing Medical University; Fudan University and other collaborators

Not yet recruiting

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Pancreatic Carcinoma

China
UNICANCER
SOLTI Breast Cancer Research Group; Vall d'Hebron Institute of Oncology; MSD...

Not yet recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC (ETNA)

Triple-negative Breast Cancer
Chuangzhen Chen

Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors (ILDRV1)

Radiotherapy | Immune Checkpoint Blockade | Metastatic Extracranial Malignant Solid Neoplasm | Resistance to Immunotherapy

China
Ruijin Hospital

Recruiting

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) (PRIMA)

Sarcoma | Sarcoma,Soft Tissue | Sarcoma of Bone

China
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Sintilimab | Lenvatinib

China
Chinese University of Hong Kong

Recruiting

Randomized Controlled Trial for Wheat Oral Immunotherapy (WOIT-RCT)

Children | Allergy;Food | Wheat Allergy

Hong Kong
Damanhour University

Recruiting

Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

Type 2 Diabetes

Egypt
Institut Curie
Roche Pharma AG; Replimune Inc.

Not yet recruiting

"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (neoBREASTIM)

Triple Negative Breast Neoplasms

France
National Cancer Institute (NCI)

Not yet recruiting

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Metastatic Melanoma | Locally Advanced Melanoma | Metastatic Alveolar Soft Part Sarcoma | Metastatic Non Small Cell Lung Cancer | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma | Metastatic Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer | Locally... and other conditions

United States
Northern Jiangsu Province People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Neoadjuvant Therapy | Radiotherapy | Immunotherapy

China
Lebanese University
Haykel Hospital

Recruiting

Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms (CAT_PB)

Cardiovascular Diseases | Immune System Diseases | Cancer | Breast Cancer | Hepatocellular Carcinoma | Lung Cancer | Chemotherapy | Solid Tumor | Prostate Cancer | Thromboembolism | Colon Cancer | Immunotherapy | Inflammatory Diseases

Lebanon
GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
Imugene Limited

Recruiting

A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) (OASIS)

Solid Tumor, Adult

United States
Peking Union Medical College Hospital

Recruiting

Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma

Advanced Soft Tissue Sarcoma

China
Lars Olaf Cardell

Recruiting

Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT (ILIT vs SLIT)

Allergic Rhinitis Due to Grass Pollen

Sweden
ImmunityBio, Inc.

Not yet recruiting

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Glioblastoma
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Camrelizumab | Lenvatinib

China
GERCOR - Multidisciplinary Oncology Cooperative...

Recruiting

Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study (DEWI)

Gastric Adenocarcinoma | Adenocarcinoma - GEJ

France
CatalYm GmbH

Recruiting

Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer

Adult Solid Tumor | Bladder Cancer

Italy
Guo Xufeng

Recruiting

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Adjuvant Therapy | Neoadjuvant Chemoimmunotherapy

China
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Sheba Medical Center

Not yet recruiting

Hepatopulmonary Radio-sterilization With Immunotherapy (TROS-8)

Rectal Cancer | Colon Cancer | Liver Metastasis Colon Cancer

Israel
Alentis Therapeutics AG

Recruiting

Study of ALE.C04 in Patients With Head and Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Hong Kong, Singapore, Spain, Canada, Italy
Hospital General Universitario Gregorio Marañon
Instituto de Salud Carlos III

Recruiting

Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2) (THYTECH2)

Systemic Inflammatory Response Syndrome

Spain
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer (RCT-PAAG)

Pancreatic Adenocarcinoma Metastatic

China
NYU Langone Health
National Institute on Drug Abuse (NIDA)

Not yet recruiting

Assessing Optimal XRB Initiation Points in Jail

Opioid Use Disorder

United States
The University of Texas Medical Branch, Galveston

Recruiting

The Gut Microbiome and Immunotherapy Response in Solid Cancers

Cancer

United States
University College, London

Recruiting

Cancer Treatment Related Cardiovascular Toxicity: Comprehensive Myocardial and Vascular Phenotyping (PC-TOX)

Cardiovascular Diseases | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Cardiotoxicity | Malignancy | Oesophagus Cancer | Fluorouracil Adverse Reaction

United Kingdom
Zhejiang Cancer Hospital

Recruiting

Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy

Cholangiocarcinoma | Biliary Tract Tumor

China
University of Saskatchewan

Not yet recruiting

Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer

Liver Metastasis Colon Cancer
Dr Cipto Mangunkusumo General Hospital

Recruiting

Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma

Indonesia
Cancer Research UK
Aleta BioTherapeutics

Recruiting

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell

United Kingdom
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
National Cancer Institute (NCI)

Not yet recruiting

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Testicular Germ Cell Tumors

United States
Sun Yat-sen University
First People's Hospital of Foshan; The First Affiliated Hospital, Guangzhou... and other collaborators

Recruiting

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC (HAIC)

Hepatocellular Carcinoma | Chemotherapy Effect | Chemotherapeutic Toxicity

China
Fudan University
Shanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Ninth People's Hospital... and other collaborators

Recruiting

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Hypopharyngeal Cancer | Larynx Cancer

China
Hamilton Health Sciences Corporation
Canadian Institutes of Health Research (CIHR); AAAAI Foundation

Recruiting

Thresholds In Food Allergy evaluaTion And predictioN (TITAN)

Food Allergy | Tree Nut Allergy

Canada
Hubei Cancer Hospital

Recruiting

Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Radiotherapy | Immunotherapy | Advanced Non-Small Cell Squamous Lung Cancer

China
Mahidol University

Recruiting

Comparison Efficacy Between Two Different Frequency of Maintenance Dose Oral Immunotherapy

Immunotherapy | Wheat Hypersensitivity

Thailand
RenJi Hospital
Shanghai Zhongshan Hospital; Ruijin Hospital

Recruiting

A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy

China
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
Hubei Cancer Hospital

Recruiting

Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients

Metastatic Lung Cancer | Elderly Patients

China
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
Sidney Kimmel Comprehensive Cancer Center at Johns...
Fibrolamellar Cancer Foundation; Dracen Pharmaceuticals, Inc.

Recruiting

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Fibrolamellar Hepatocellular Carcinoma

United States
University Hospital, Bordeaux

Not yet recruiting

Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies (COCKPI-T)

Lung Neoplasm | Cancer Associated Fibroblast | Myeloid-Derived Suppressive Cells Immunosuppression

France

Search clinical trials for: Sublingual immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations